These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16307630)

  • 1. Buprenorphine retention in primary care.
    Stein MD; Cioe P; Friedmann PD
    J Gen Intern Med; 2005 Nov; 20(11):1038-41. PubMed ID: 16307630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services.
    Whitley SD; Kunins HV; Arnsten JH; Gourevitch MN
    J Subst Abuse Treat; 2007 Jul; 33(1):85-90. PubMed ID: 17588493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
    Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
    Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
    Fhima A; Henrion R; Lowenstein W; Charpak Y
    Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
    Soeffing JM; Martin LD; Fingerhood MI; Jasinski DR; Rastegar DA
    J Subst Abuse Treat; 2009 Dec; 37(4):426-30. PubMed ID: 19553061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early experience with Suboxone maintenance therapy in Hungary.
    Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients.
    Vigezzi P; Guglielmino L; Marzorati P; Silenzio R; De Chiara M; Corrado F; Cocchi L; Cozzolino E
    J Subst Abuse Treat; 2006 Jul; 31(1):3-7. PubMed ID: 16814005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public policy statement on Office-Based Opioid Agonist Treatment (OBOT).
    J Addict Dis; 2005; 24(3):153-61. PubMed ID: 16186090
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
    Johnson RE; Chutuape MA; Strain EC; Walsh SL; Stitzer ML; Bigelow GE
    N Engl J Med; 2000 Nov; 343(18):1290-7. PubMed ID: 11058673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients.
    Wittchen HU; Apelt SM; Soyka M; Gastpar M; Backmund M; Gölz J; Kraus MR; Tretter F; Schäfer M; Siegert J; Scherbaum N; Rehm J; Bühringer G
    Drug Alcohol Depend; 2008 Jun; 95(3):245-57. PubMed ID: 18337025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J; Mutch C
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Maintenance treatment for opioid dependence in care centers: the OPPIDUM program of the Evaluation and Information Centers for Drug Addiction].
    Thirion X; Barrau K; Micallef J; Haramburu F; Lowenstein W; Sanmarco JL
    Ann Med Interne (Paris); 2000 Apr; 151 Suppl A():A10-7. PubMed ID: 10855372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of buprenorphine maintenance in office-based practice.
    Magura S; Lee SJ; Salsitz EA; Kolodny A; Whitley SD; Taubes T; Seewald R; Joseph H; Kayman DJ; Fong C; Marsch LA; Rosenblum A
    J Addict Dis; 2007; 26(2):13-23. PubMed ID: 17594994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)].
    Duburcq A; Charpak Y; Blin P; Madec L
    Rev Epidemiol Sante Publique; 2000 Aug; 48(4):363-73. PubMed ID: 11011303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.
    Maremmani I; Pani PP; Pacini M; Perugi G
    J Subst Abuse Treat; 2007 Jul; 33(1):91-8. PubMed ID: 17588494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation.
    Collins ED; Horton T; Reinke K; Amass L; Nunes EV
    J Subst Abuse Treat; 2007 Mar; 32(2):167-75. PubMed ID: 17306725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.